MAP Pharmaceuticals, Inc.

• About Us 
  • Message from the CEO
  • Management Team
  • Board of Directors
  • Partnering
  • Contact Us
• Product Pipeline 
  • Pediatric Asthma Therapy
  • Inhaled Migraine Therapy
  • Asthma/COPD Therapy
  • Inhaled Diabetes Therapy
• Investor Relations 
  • Press Releases
  • Calendar of Events
  • Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • SEC Filings
  • Stock Information
  • Contact Us
• Science & Technology 
• Publications 
  • Asthma
  • Migraine
  • Aerosol Science and Technology

Navigating the Path to Better Medicine

MAP Pharmaceuticals develops and plans to commercialize new drugs for children and adults who suffer from diseases that we believe are not treated adequately by currently available medicine. We expect to initiate two Phase 3 clinical programs by early 2008 with product candidates to treat pediatric asthma and migraine headache.